Acting

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Markforged Announces Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
Engineering, Technology, Manufacturing, Software, Other Manufacturing, Hardware, CFO, Acquisition, X7, OEM, Annual report, Investment, 3D, Growth, Sale, Acting, Health, GAAP, Corporate development, Webcast, Automation, Security (finance), Partnership, Cryptocurrency

Markforged Holding Corporation (NYSE: MKFG) (the “Company”), the company strengthening manufacturing resiliency by enabling industrial production at the point of need, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Markforged Holding Corporation (NYSE: MKFG) (the “Company”), the company strengthening manufacturing resiliency by enabling industrial production at the point of need, today announced its financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue was $24.2 million, up 20.4% sequentially from the third quarter of 2023, and down from $29.7 million in the fourth quarter of 2022.
  • While slow capital expenditures in 2023 delayed system sales, Markforged delivered 20% sequential revenue growth in the fourth quarter.
  • During the fourth quarter, Markforged expanded its relationship with Automation Alley through the sale of an additional 125 OnyxPro printers for its Project DIAMOnD initiative.

Torridon Law PLLC Announces Major Expansion

Retrieved on: 
Wednesday, January 17, 2024
Drug, Special, House, Executive (government), Private law, Government, Public, Supreme court, Antonin Scalia, Kirkland, WarnerMedia, CIA, Counsel, Assistant, Policy, Richard Nixon, Law, Ullyot, District court, Dominion Energy, Investment, Senate, Debate, ESL Investments, Private practice, SIGPR, Cabinet, Honors colleges and programs, White, Acting, Supreme, Justice, Verizon Communications, White House Counsel, Administrative Reforms Commission, Clarence Thomas, National Commission, Associate, Cipollone, Multimedia, Commerce, Liberty, Equal opportunity, Conference, IPO, Ronald Reagan, Becket Law, Georgetown University Law Center, Private sector, Kirkland & Ellis, House of Representatives, Representative

In private practice, Philbin spent over fifteen years as a litigation partner at a major international law firm.

Key Points: 
  • In private practice, Philbin spent over fifteen years as a litigation partner at a major international law firm.
  • She was a tenured professor at Syracuse University College of Law and a visiting scholar at the Georgetown University Law Center.
  • Before his time in public service, he represented clients at a major international law firm.
  • After his clerkship, he worked as a Constitutional Law Fellow at the Becket Fund for Religious Liberty.

Wilson Sonsini Adds Former FTC and DOJ Veterans to Antitrust Team as Partners

Retrieved on: 
Monday, January 8, 2024
Consulting, Legal, Professional Services, Business, Intellectual property, University, Congress, Commerce, FTC, Assistant, Multimedia, Constitution, Privacy, Knowledge, District court, Policy, Harvard University, Federal Trade Commission, Senate, Chambers and Partners, Private practice, The Honourable, Internet, Counsel, Exercise, Vanderbilt University Law School, Private law, Telecommunications, Acquisition, Supreme court, Supreme, Internet access, DOJ, Baker Botts, Social media, Acting

The addition of Ohlhausen and Owings—both of whom have held senior, high-level regulatory agency roles—represents a significant move by Wilson Sonsini to bolster its well-respected antitrust and competition practice.

Key Points: 
  • The addition of Ohlhausen and Owings—both of whom have held senior, high-level regulatory agency roles—represents a significant move by Wilson Sonsini to bolster its well-respected antitrust and competition practice.
  • She would go on to hold various positions within the FTC over the next 12 years.
  • “Wilson Sonsini is renowned for its destination antitrust and competition practice, meeting the full spectrum of clients' needs,” Ohlhausen said.
  • Wilson Sonsini’s elite antitrust and competition practice group represents clients in high-stakes antitrust litigation, mergers, and criminal and civil investigations, in addition to providing valuable counseling on business strategy.

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer as MASH Asset BOS-580 Accelerates in Phase 2 Clinical Program

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Yale University, Doctor of Pharmacy, Hepatocellular carcinoma, Pharmacy, CMO, Roche, Medication, Bristol Myers Squibb, Hepatology, Intercept Pharmaceuticals, Doctor of Philosophy, Nobel Prize, HCV, University, Fatty liver disease, Knowledge, MASH, AbbVie, Acting, Pharmaceutical industry

Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO).

Key Points: 
  • Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO).
  • Boston Pharmaceuticals is a clinical stage biopharmaceutical company with a lead investigational asset in non-alcoholic steatohepatitis (MASH), BOS-580, currently in Phase 2 development, and a Phase 1 asset, BOS-342, in development for hepatocellular carcinoma.
  • Dr. Lopez-Talavera joined Boston Pharmaceuticals in August 2023 and has since been instrumental in accelerating the development of BOS-580, which will advance to pivotal studies in 2024.
  • He completed a post-doctoral fellowship at Yale University and served as an Assistant Professor at the University of Pittsburgh.

PsiQuantum Announces New Government Advisory Board with Decades of Combined Public Service Across the White House, Departments of Defense and Commerce, Intelligence Community, and the U.S. Congress

Retrieved on: 
Thursday, November 30, 2023
Research, Other Defense, Hardware, Technology, White House, Federal Government, Defense, Semiconductor, Security, Science, Engineering, Military, Public Policy, Government, Manufacturing, CHIPS, Economics, United Nations Security Council, USN, Entrepreneurship, State, RET, CEA, WestExec Advisors, Congress, Policy, Australian Intelligence Community, Duke University, Commerce, CHIPS and Science Act, Multimedia, House, Triple accreditation, Information, CNAS, Innovation, National security council, Principal, Public policy, Rhode Island General Assembly, Military intelligence, University, GAB, Intelligence, National security, White, Acting, Fuqua School, Former, Second Continental Congress, Pacific Ocean, Mississippi Industrial College, Intelligence community, Langevin, Council of Economic Advisers, NGA, National Geospatial-Intelligence Agency, Pharmaceutical industry, Management, Business, Computer security

Although currently focused on priorities pertaining to U.S. Government, PsiQuantum plans to expand the Government Advisory Board to include leaders from other allied nations as well.

Key Points: 
  • Although currently focused on priorities pertaining to U.S. Government, PsiQuantum plans to expand the Government Advisory Board to include leaders from other allied nations as well.
  • (Photos: PsiQuantum)
    The creation of the Government Advisory Board is a natural progression of the company’s longstanding partnerships with the U.S. and allied governments.
  • Through this Board, PsiQuantum will also be better placed to continue its work developing public-private partnerships across the U.S. and allied governments.
  • “We are grateful for the deep experience and perspective that each member of the Government Advisory Board will be able to share.

Runway Growth Finance Corp. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Lead, Office of Foreign Assets Control, Fidelis Cybersecurity, Runway, Audit committee, Sale, Commerce Bank & Trust Company, Investment, Webcast, National Association, Credit, U.S. Bancorp, Cryptocurrency, Security (finance), Custodian, Acting

MENLO PARK, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Total net assets at the end of the second quarter of 2023 was $573.9 million, down 0.95% from $579.4 million in the prior year period.
  • The Company ended the quarter with a core leverage ratio of approximately 97%, compared to 104% for the quarter ended March 31, 2023.
  • On August 1, 2023, the Company’s board of directors declared a regular quarterly distribution of $0.40 per share for the third quarter of 2023, payable on August 31, 2023, to stockholders of record as of August 15, 2023.
  • Runway Growth will hold a conference call to discuss its second quarter ended June 30, 2023 financial results at 2:00 p.m. PT (5:00 p.m.

Former Acting Deputy Secretary of Defense Christine Fox Joins Muon Space Board

Retrieved on: 
Tuesday, August 8, 2023
Pentagon, Face, National security, Fox, CAPE, Climate change, Strategic planning, Director of Cost Assessment and Program Evaluation, Acting, U.S. Department of Defense Strategy for Operating in Cyberspace, Climate, Program evaluation, Deep, Renewable energy, Management, Defense

MOUNTAIN VIEW, Calif., Aug. 8, 2023 /PRNewswire/ -- Muon Space, a climate constellation company revolutionizing the way Earth is monitored from space, proudly announces the appointment of former Acting Deputy Secretary of Defense Christine H. Fox, to its Board of Directors. Fox brings a distinguished career in national security and strong commitment to addressing the far-reaching impacts of Climate Change. Her appointment significantly advances Muon Space's efforts at the intersection of Climate Change and National Security.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 8, 2023 /PRNewswire/ -- Muon Space , a climate constellation company revolutionizing the way Earth is monitored from space, proudly announces the appointment of former Acting Deputy Secretary of Defense Christine H. Fox, to its Board of Directors.
  • She served as Acting Deputy Secretary of Defense, the Department of Defense's second highest-ranking official, from 2013 to 2014, where she was responsible for overseeing the Pentagon's annual budget and strategic planning.
  • With Fox joining the Board, Muon Space solidifies its position as an industry leader, poised to drive sustainable solutions for a rapidly changing planet.
  • Jonny Dyer, CEO of Muon Space, expressed his excitement for Fox's appointment, stating, "We are honored and humbled to welcome Christine Fox to our Board of Directors.

RGS Announces Arrival of new Acting Chief Executive Officer Paul Smith

Retrieved on: 
Thursday, June 29, 2023
Other Defense, Security, Data Management, Technology, Law Enforcement, Emergency Services, Other Policy Issues, Healthcare Reform, Small Business, Homeland Security, Professional Services, Defense, Congressional News, Views, Public Policy, Government, Software, Internet, Public sector, Senior, American Public Transportation Association, Proxy, Proxy board, Multimedia, RGS, Acting, Red Hat, Growth, Management

Rancher Government Solutions (RGS), today announces the arrival of Paul Smith, formerly the Senior Vice President and General Manager of the North American Public Sector at Red Hat, as Acting Chief Executive Officer for RGS.

Key Points: 
  • Rancher Government Solutions (RGS), today announces the arrival of Paul Smith, formerly the Senior Vice President and General Manager of the North American Public Sector at Red Hat, as Acting Chief Executive Officer for RGS.
  • Lynne Chamberlain has decided to retire as the current Chief Executive Officer.
  • Lynne has been instrumental in RGS’s growth since she joined RGS in November 2020 and has overseen RGS obtaining its facility security clearance.
  • I wish them all the very best.”
    Incoming Acting CEO of RGS, Paul Smith said, “I would like to thank the Proxy Board for the opportunity to join RGS as its Acting CEO.

Colony Bank Names Derek Shelnutt Chief Financial Officer

Retrieved on: 
Thursday, June 29, 2023
Banking, Accounting, Professional Services, Finance, Bachelor, University, Senior, Shay Shelnutt, Crown Estate, Colonial Bank (United States), Certified Public Accountant, American Institute of Certified Public Accountants, Multimedia, Treasury management, Treasury, Business administration, Acting, Bank, American Institute, Management, Auditor, Colony

Colony Bank announced today that Derek Shelnutt has been named Executive Vice President and Chief Financial Officer of the Bank, effective July 1, 2023.

Key Points: 
  • Colony Bank announced today that Derek Shelnutt has been named Executive Vice President and Chief Financial Officer of the Bank, effective July 1, 2023.
  • Shelnutt previously served as Senior Vice President, Chief Accounting Officer, and Acting Chief Financial Officer of the Bank since January 2023.
  • Shelnutt will continue to serve as Senior Vice President and Chief Accounting Officer of Colony Bankcorp., Inc. and Heath Fountain, Chief Executive Officer, will continue to serve as Acting Chief Financial Officer of Colony Bankcorp., Inc.
  • Commenting on the announcement, Heath Fountain, Chief Executive Officer, said, “We’re proud to promote Derek to Chief Financial Officer for Colony Bank, a role that he performed exceptionally well on an interim basis.